Published on April 29, 2026
mbiomics GmbH, a Munich-based techbio venture, was operating within the burgeoning field of microbiome therapeutics, focusing on innovative solutions for cancer treatment. The company has made notable strides in developing a live bacterial product aimed at enhancing immune checkpoint inhibitors, which currently represent a significant component of cancer therapies.
- Rural America Pushes Back Against AI Data Centers
- Nodewave Launches Free Redesign Tool Changing Creative Workflows
- Nex.ai Launches WUPHF: A New Era for AI Collaboration
- AI Drives Growth at ServiceNow, According to CEO
- MAXIA Oracle Transforms AI Pricing Dynamics
- Meta Cuts Workforce by 10% Amid AI Spending Surge